Decision to list a new brand of iron polymaltose (Ferrosig)

Medicines

Decision

We’re pleased to announce a decision to list a new brand of iron polymaltose inj 50 mg per ml, 2 ml ampoule (Ferrosig) supplied by Sigma Healthcare.

Ferrosig will be listed without funding restrictions from 1 January 2019.

Who we think will be most interested

  • Health care professionals involved in the treatment of iron deficiency
  • Community and hospital pharmacists, wholesalers and suppliers
  • Patients needing regular iron supplementation

Detail about this decision

The currently listed brand of iron polymaltose, Ferrum H (supplied by Vifor), is being discontinued and will be delisted from the Pharmaceutical Schedule on 1 April 2019.

To ensure continuous supply of iron polymaltose, PHARMAC has reached an agreement with Sigma Healthcare for ongoing supply of its brand of iron polymaltose, Ferrosig.

Ferrosig is Medsafe approved and, like Ferrum H, is an ampoule for injection, containing 50 mg per ml, 2 ml. Ferrosig will be listed at $34.50 per pack of 5 ampoules.

As with Ferrum H, Ferrosig will be fully subsidised and funded without restriction. 

Enquiries

If you have any questions about this decision, you can email us at enquiry@pharmac.govt.nz; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.